VANCOUVER—The federal government’s plan to lower the cost of patented pharmaceuticals in Canada through new regulations seriously risks limiting patient access to new innovative drugs, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.
“Establishing drug prices has always been a balance between affordability and accessibility, but by markedly shifting the scales towards lower prices, Canadian patients will likely have less access to life-saving drugs,” said Kristina Acri, Fraser Institute senior fellow, associate professor of economics at Colorado College and author of Implications of the Proposed Changes to Canada’s Pharmaceutical Pricing Regulations.